Interstitial lung diseases in children

Annick Clement, Nadia Nathan, Ralph Epaud, Brigitte Fauroux, Harriet Corvol, Annick Clement, Nadia Nathan, Ralph Epaud, Brigitte Fauroux, Harriet Corvol

Abstract

Interstitial lung disease (ILD) in infants and children comprises a large spectrum of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. These disorders are characterized by inflammatory and fibrotic changes that affect alveolar walls. Typical features of ILD include dyspnea, diffuse infiltrates on chest radiographs, and abnormal pulmonary function tests with restrictive ventilatory defect and/or impaired gas exchange. Many pathological situations can impair gas exchange and, therefore, may contribute to progressive lung damage and ILD. Consequently, diagnosis approach needs to be structured with a clinical evaluation requiring a careful history paying attention to exposures and systemic diseases. Several classifications for ILD have been proposed but none is entirely satisfactory especially in children. The present article reviews current concepts of pathophysiological mechanisms, etiology and diagnostic approaches, as well as therapeutic strategies. The following diagnostic grouping is used to discuss the various causes of pediatric ILD: 1) exposure-related ILD; 2) systemic disease-associated ILD; 3) alveolar structure disorder-associated ILD; and 4) ILD specific to infancy. Therapeutic options include mainly anti-inflammatory, immunosuppressive, and/or anti-fibrotic drugs. The outcome is highly variable with a mortality rate around 15%. An overall favorable response to corticosteroid therapy is observed in around 50% of cases, often associated with sequelae such as limited exercise tolerance or the need for long-term oxygen therapy.

Figures

Figure 1
Figure 1
Mechanisms and pathways involved in the response of the alveolar structure of the lung to injury. Abbreviation: Transforming Growth Factor (TGF)-β.
Figure 2
Figure 2
Alveolar structure disorder-associated ILD and ER stress. The (Endoplasmic Reticulum) ER and its protein maturation machinery allow the synthesis of mature secretory and membrane proteins with specific folded conformation. In situations of stress induced by genetic mutations or environmental factors, unfolded or misfolded proteins are retained in the ER and induce a defence mechanism called the ER stress response. The induction of ER chaperones is critical to increase the ER folding capacity allowing the production of correctly folded protein. When this defence mechanism is impaired, the misfolded proteins can either be degraded by the proteasome or form protein aggregates. Protein aggregates are toxic and can cause conformational diseases. Within the alveolar epithelium, misfolding of SP-C could trigger induction of intra-cellular aggregate formation and ER stress, with consequently development of alveolar structure disorder-associated ILD and conformational disease.
Figure 3
Figure 3
Search for ILD etiology in children. ILD is defined by the presence of diffuse infiltrates on chest radiographs or chest high resolution computed tomography, and abnormal pulmonary function tests with evidence of a restrictive ventilatory defect (in older children) and/or impaired gas exchange. The search for etiology requires a systematic step-by-step diagnostic strategy for identifying: exposure-related ILD; systemic disease-associated ILD; alveolar structure disorder-associated ILD; and ILD specific to infancy.
Figure 4
Figure 4
Alveolar structure disorder-associated ILD. Depending on the causes, the alveolar structure components can be involved differently and serve as primary targets of the underlying pathological processes. Based on history, clinical presentation, BAL and lung tissue information, the disorders can be gathered in groups according to the predominant alveolar targets: epithelium, vascular or interstitial components.

References

    1. Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol. 2002;34(1):23–9. doi: 10.1002/ppul.10125.
    1. Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med. 1997;156(3 Pt 1):939–42.
    1. Bolliger CT CU, du Bois RM, Egan JJ. Diffuse parenchymal lung disease. Cape Town: Karger; 2007.
    1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1301–15.
    1. ATS. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus. Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.
    1. Fan LL, Langston C. Pediatric interstitial lung disease: children are not small adults. Am J Respir Crit Care Med. 2002;165(11):1466–7. doi: 10.1164/rccm.2204012.
    1. Bush A, Nicholson AG. Paediatric interstitial lung disease. European Respiratory Society; 2009.
    1. Deutsch GH, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA. et al.Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med. 2007;176(11):1120–8. doi: 10.1164/rccm.200703-393OC.
    1. Clement A. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J. 2004;24(4):686–97. doi: 10.1183/09031936.04.00089803.
    1. Ficker JH. Physiology and pathophysiology of bronchial secretion. Pneumologie. 2008;62(Suppl 1):S11–3. doi: 10.1055/s-2007-959215.
    1. Clement A, Eber E. Interstitial lung diseases in infants and children. Eur Respir J. 2008;31(3):658–66. doi: 10.1183/09031936.00004707.
    1. Hartl D, Griese M. Interstitial lung disease in children -- genetic background and associated phenotypes. Respir Res. 2005;6(1):32. doi: 10.1186/1465-9921-6-32.
    1. Clement A, Henrion-Caude A, Fauroux B. The pathogenesis of interstitial lung diseases in children. Paediatr Respir Rev. 2004;5(2):94–7. doi: 10.1016/j.prrv.2004.01.002.
    1. Corvol H, Flamein F, Epaud R, Clement A, Guillot L. Lung alveolar epithelium and interstitial lung disease. Int J Biochem Cell Biol. 2009;41(8-9):1643–51. doi: 10.1016/j.biocel.2009.02.009.
    1. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008;10(2):287–301. doi: 10.1089/ars.2007.1897.
    1. Wells AU, Hogaboam CM. Update in diffuse parenchymal lung disease 2007. Am J Respir Crit Care Med. 2008;177(6):580–4. doi: 10.1164/rccm.200801-056UP.
    1. Ley K, Zarbock A. From lung injury to fibrosis. Nat Med. 2008;14(1):20–1. doi: 10.1038/nm0108-20.
    1. Studer SM, Kaminski N. Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc. 2007;4(1):85–91. doi: 10.1513/pats.200607-139JG.
    1. Thannickal VJ, Toews GB, White ES, Lynch JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417. doi: 10.1146/annurev.med.55.091902.103810.
    1. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42. doi: 10.1038/nrm1835.
    1. Fattman CL. Apoptosis in pulmonary fibrosis: too much or not enough? Antioxid Redox Signal. 2008;10(2):379–85. doi: 10.1089/ars.2007.1907.
    1. Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal. 2008;10(2):333–42. doi: 10.1089/ars.2007.1914.
    1. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol. 2007;37(1):38–47. doi: 10.1165/rcmb.2006-0353OC.
    1. Kim KK, Chapman HA. Endothelin-1 as initiator of epithelial-mesenchymal transition: potential new role for endothelin-1 during pulmonary fibrosis. Am J Respir Cell Mol Biol. 2007;37(1):1–2. doi: 10.1165/rcmb.2007-0001ED.
    1. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30(5):835–9. doi: 10.1183/09031936.00069307.
    1. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006;3(4):350–6. doi: 10.1513/pats.200601-001TK.
    1. Yamasaki M, Kang HR, Homer RJ, Chapoval SP, Cho SJ, Lee BJ. et al.P21 regulates TGF-beta1-induced pulmonary responses via a TNF-alpha-signaling pathway. Am J Respir Cell Mol Biol. 2008;38(3):346–53. doi: 10.1165/rcmb.2007-0276OC.
    1. Garcia-Alvarez J, Ramirez R, Sampieri CL, Nuttall RK, Edwards DR, Selman M. et al.Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):13–21.
    1. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3(4):383–8. doi: 10.1513/pats.200601-012TK.
    1. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3(4):364–72. doi: 10.1513/pats.200601-003TK.
    1. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008;5(3):e62. doi: 10.1371/journal.pmed.0050062.
    1. Shannon JM, Hyatt BA. Epithelial-mesenchymal interactions in the developing lung. Annu Rev Physiol. 2004;66:625–45. doi: 10.1146/annurev.physiol.66.032102.135749.
    1. Schock F, Perrimon N. Molecular mechanisms of epithelial morphogenesis. Annu Rev Cell Dev Biol. 2002;18:463–93. doi: 10.1146/annurev.cellbio.18.022602.131838.
    1. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81. doi: 10.1083/jcb.200601018.
    1. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M. et al.Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(8):838–46. doi: 10.1164/rccm.200802-313OC.
    1. Beers MF, Mulugeta S. Surfactant protein C biosynthesis and its emerging role in conformational lung disease. Annu Rev Physiol. 2005;67:663–96. doi: 10.1146/annurev.physiol.67.040403.101937.
    1. Mulugeta S, Maguire JA, Newitt JL, Russo SJ, Kotorashvili A, Beers MF. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L720–9. doi: 10.1152/ajplung.00025.2007.
    1. Bridges JP, Xu Y, Na CL, Wong HR, Weaver TE. Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol. 2006;172(3):395–407. doi: 10.1083/jcb.200508016.
    1. Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB. et al.Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol. 2008;294(6):L1119–26. doi: 10.1152/ajplung.00382.2007.
    1. Mimura N, Hamada H, Kashio M, Jin H, Toyama Y, Kimura K. et al.Aberrant quality control in the endoplasmic reticulum impairs the biosynthesis of pulmonary surfactant in mice expressing mutant BiP. Cell Death Differ. 2007;14(8):1475–85. doi: 10.1038/sj.cdd.4402151.
    1. Doan ML, Guillerman RP, Dishop MK, Nogee LM, Langston C, Mallory GB. et al.Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax. 2008;63(4):366–73. doi: 10.1136/thx.2007.083766.
    1. Matsumura Y, Ban N, Inagaki N. Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2008;295(4):L698–707. doi: 10.1152/ajplung.90352.2008.
    1. Yoshida I, Ban N, Inagaki N. Expression of ABCA3, a causative gene for fatal surfactant deficiency, is up-regulated by glucocorticoids in lung alveolar type II cells. Biochem Biophys Res Commun. 2004;323(2):547–55. doi: 10.1016/j.bbrc.2004.08.133.
    1. Stevens PA, Pettenazzo A, Brasch F, Mulugeta S, Baritussio A, Ochs M. et al.Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene. Pediatr Res. 2005;57(1):89–98. doi: 10.1203/01.PDR.0000147567.02473.5A.
    1. Guillot L, Epaud R, Thouvenin G, Jonard L, Mohsni A, Couderc R. et al.New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet. 2009;46(7):490–4. doi: 10.1136/jmg.2009.066829.
    1. Johnson AL, Braidotti P, Pietra GG, Russo SJ, Kabore A, Wang WJ. et -translational processing of surfactant protein-C proprotein: targeting motifs in the NH(2)-terminal flanking domain are cleaved in late compartments. Am J Respir Cell Mol Biol. 2001;24(3):253–63.
    1. Hamdan H, Liu H, Li C, Jones C, Lee M, deLemos R. et al.Structure of the human Nkx2.1 gene. Biochim Biophys Acta. 1998;1396(3):336–48.
    1. Warburton D, Perin L, Defilippo R, Bellusci S, Shi W, Driscoll B. Stem/progenitor cells in lung development, injury repair, and regeneration. Proc Am Thorac Soc. 2008;5(6):703–6. doi: 10.1513/pats.200801-012AW.
    1. Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311(5769):1880–5. doi: 10.1126/science.1110542.
    1. Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D. Telomerase in alveolar epithelial development and repair. Am J Physiol Lung Cell Mol Physiol. 2000;279(6):L1191–8.
    1. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006;107(7):2680–5. doi: 10.1182/blood-2005-07-2622.
    1. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD. et al.Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008;105(35):13051–6. doi: 10.1073/pnas.0804280105.
    1. Gurtner GC, Callaghan MJ, Longaker MT. Progress and potential for regenerative medicine. Annu Rev Med. 2007;58:299–312. doi: 10.1146/annurev.med.58.082405.095329.
    1. Colwell AS, Longaker MT, Lorenz HP. Mammalian fetal organ regeneration. Adv Biochem Eng Biotechnol. 2005;93:83–100.
    1. Orlandi A, Francesconi A, Marcellini M, Ferlosio A, Spagnoli LG. Role of ageing and coronary atherosclerosis in the development of cardiac fibrosis in the rabbit. Cardiovasc Res. 2004;64(3):544–52. doi: 10.1016/j.cardiores.2004.07.024.
    1. Beggs ML, Nagarajan R, Taylor-Jones JM, Nolen G, Macnicol M, Peterson CA. Alterations in the TGFbeta signaling pathway in myogenic progenitors with age. Aging Cell. 2004;3(6):353–61. doi: 10.1111/j.1474-9728.2004.00135.x.
    1. Komi-Kuramochi A, Kawano M, Oda Y, Asada M, Suzuki M, Oki J. et al.Expression of fibroblast growth factors and their receptors during full-thickness skin wound healing in young and aged mice. J Endocrinol. 2005;186(2):273–89. doi: 10.1677/joe.1.06055.
    1. Pomerantz J, Blau HM. Nuclear reprogramming: a key to stem cell function in regenerative medicine. Nat Cell Biol. 2004;6(9):810–6. doi: 10.1038/ncb0904-810.
    1. Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res. 2007;24(5):819–41. doi: 10.1007/s11095-006-9216-x.
    1. Fauroux B, Epaud R, Clement A. Clinical presentation of interstitial lung disease in children. Paediatr Respir Rev. 2004;5(2):98–100. doi: 10.1016/j.prrv.2004.01.003.
    1. Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol. 2004;38(5):369–78. doi: 10.1002/ppul.20114.
    1. Copley SJ, Bush A. HRCT of paediatric lung disease. Paediatr Respir Rev. 2000;1(2):141–7. doi: 10.1053/prrv.2000.0040.
    1. Klusmann M, Owens C. HRCT in paediatric diffuse interstitial lung disease--a review for 2009. Pediatr Radiol. 2009;39(Suppl 3):471–81. doi: 10.1007/s00247-009-1200-2.
    1. Vrielynck S, Mamou-Mani T, Emond S, Scheinmann P, Brunelle F, de Blic J. Diagnostic value of high-resolution CT in the evaluation of chronic infiltrative lung disease in children. AJR Am J Roentgenol. 2008;191(3):914–20. doi: 10.2214/AJR.07.2710.
    1. Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P. et official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007;175(12):1304–45. doi: 10.1164/rccm.200605-642ST.
    1. Beydon N. Pulmonary function testing in young children. Paediatr Respir Rev. 2009;10(4):208–13. doi: 10.1016/j.prrv.2009.03.001.
    1. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 1997;111(1):51–7. doi: 10.1378/chest.111.1.51.
    1. Javaheri S, Sicilian L. Lung function, breathing pattern, and gas exchange in interstitial lung disease. Thorax. 1992;47(2):93–7. doi: 10.1136/thx.47.2.93.
    1. Kerem E, Bentur L, England S, Reisman J, O'Brodovich H, Bryan AC. et al.Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis. J Pediatr. 1990;116(1):61–7. doi: 10.1016/S0022-3476(05)81646-4.
    1. de Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E. et al.Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. Eur Respir J. 2000;15(1):217–31.
    1. Grebski E, Hess T, Hold G, Speich R, Russi E. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest. 1992;102(6):1794–9. doi: 10.1378/chest.102.6.1794.
    1. Refabert L, Rambaud C, Mamou-Mani T, Scheinmann P, de Blic J. Cd1a-positive cells in bronchoalveolar lavage samples from children with Langerhans cell histiocytosis. J Pediatr. 1996;129(6):913–5. doi: 10.1016/S0022-3476(96)70038-0.
    1. Midulla F, Strappini PM, Ascoli V, Villa MP, Indinnimeo L, Falasca C. et al.Bronchoalveolar lavage cell analysis in a child with chronic lipid pneumonia. Eur Respir J. 1998;11(1):239–42. doi: 10.1183/09031936.98.11010239.
    1. Tabak L, Yilmazbayhan D, Kilicaslan Z, Tascioglu C, Agan M. Value of bronchoalveolar lavage in lipidoses with pulmonary involvement. Eur Respir J. 1994;7(2):409–11. doi: 10.1183/09031936.94.07020409.
    1. Knauer-Fischer S, Ratjen F. Lipid-laden macrophages in bronchoalveolar lavage fluid as a marker for pulmonary aspiration. Pediatr Pulmonol. 1999;27(6):419–22. doi: 10.1002/(SICI)1099-0496(199906)27:6<419::AID-PPUL9>;2-U.
    1. Ratjen F, Costabel U, Griese M, Paul K. Bronchoalveolar lavage fluid findings in children with hypersensitivity pneumonitis. Eur Respir J. 2003;21(1):144–8. doi: 10.1183/09031936.03.00035703a.
    1. Oermann CM, Panesar KS, Langston C, Larsen GL, Menendez AA, Schofield DE. et al.Pulmonary infiltrates with eosinophilia syndromes in children. J Pediatr. 2000;136(3):351–8. doi: 10.1067/mpd.2000.103350.
    1. Griese M, Schumacher S, Tredano M, Steinecker M, Braun A, Guttentag S. et al.Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease. Respir Res. 2005;6:80. doi: 10.1186/1465-9921-6-80.
    1. Fan LL, Lung MC, Wagener JS. The diagnostic value of bronchoalveolar lavage in immunocompetent children with chronic diffuse pulmonary infiltrates. Pediatr Pulmonol. 1997;23(1):8–13. doi: 10.1002/(SICI)1099-0496(199701)23:1<8::AID-PPUL1>;2-N.
    1. Rothenberg SS, Wagner JS, Chang JH, Fan LL. The safety and efficacy of thoracoscopic lung biopsy for diagnosis and treatment in infants and children. J Pediatr Surg. 1996;31(1):100–3. doi: 10.1016/S0022-3468(96)90328-0. discussion 3-4.
    1. Smyth RL, Carty H, Thomas H, van Velzen D, Heaf D. Diagnosis of interstitial lung disease by a percutaneous lung biopsy sample. Arch Dis Child. 1994;70(2):143–4. doi: 10.1136/adc.70.2.143.
    1. Spencer DA, Alton HM, Raafat F, Weller PH. Combined percutaneous lung biopsy and high-resolution computed tomography in the diagnosis and management of lung disease in children. Pediatr Pulmonol. 1996;22(2):111–6. doi: 10.1002/(SICI)1099-0496(199608)22:2<111::AID-PPUL6>;2-T.
    1. Langston C, Patterson K, Dishop MK, Askin F, Baker P, Chou P. et al.A protocol for the handling of tissue obtained by operative lung biopsy: recommendations of the chILD pathology co-operative group. Pediatr Dev Pathol. 2006;9(3):173–80. doi: 10.2350/06-03-0065.1.
    1. Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM. ABCA3 Mutations Associated with Pediatric Interstitial Lung Disease. Am J Respir Crit Care Med. 2005;172(8):1026–31. doi: 10.1164/rccm.200503-504OC.
    1. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344(8):573–9. doi: 10.1056/NEJM200102223440805.
    1. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004;350(13):1296–303. doi: 10.1056/NEJMoa032178.
    1. Schroeder SA, Shannon DC, Mark EJ. Cellular interstitial pneumonitis in infants. A clinicopathologic study. Chest. 1992;101(4):1065–9. doi: 10.1378/chest.101.4.1065.
    1. Nicholson AG, Kim H, Corrin B, Bush A, du Bois RM, Rosenthal M. et al.The value of classifying interstitial pneumonitis in childhood according to defined histological patterns. Histopathology. 1998;33(3):203–11. doi: 10.1046/j.1365-2559.1998.00488.x.
    1. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE. et al.MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93. doi: 10.1371/journal.pmed.0050093.
    1. Doan ML, Elidemir O, Dishop MK, Zhang H, Smith EO, Black P. et al.Serum KL-6 Differentiates Neuroendocrine Cell Hyperplasia of Infancy From the Inborn Errors of Surfactant Metabolism. Thorax. 2009;64:677–681. doi: 10.1136/thx.2008.107979.
    1. Al-Salmi QA, Walter JN, Colasurdo GN, Sockrider MM, Smith EO, Takahashi H. et al.Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest. 2005;127(1):403–7. doi: 10.1378/chest.127.1.403.
    1. Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J. et al.Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol. 2009;69(3):268–74. doi: 10.1111/j.1365-3083.2008.02222.x.
    1. Gehle K LK, Ranger C. Case Studies in Environmental Medicine (CSEM). Pediatric Environmental Health. Atlanta: US Department of health and human services. Agency for toxic substances and disease registry. Division of toxicology and environmental medicine; 2002.
    1. Martinez FJ, Keane MP. Update in diffuse parenchymal lung diseases 2005. Am J Respir Crit Care Med. 2006;173(10):1066–71. doi: 10.1164/rccm.2601011.
    1. Fan LL. Hypersensitivity pneumonitis in children. Curr Opin Pediatr. 2002;14(3):323–6. doi: 10.1097/00008480-200206000-00008.
    1. Morell F, Roger A, Reyes L, Cruz MJ, Murio C, Munoz X. Bird fancier's lung: a series of 86 patients. Medicine (Baltimore) 2008;87(2):110–30. doi: 10.1097/MD.0b013e31816d1dda.
    1. Venkatesh P, Wild L. Hypersensitivity pneumonitis in children: clinical features, diagnosis, and treatment. Paediatr Drugs. 2005;7(4):235–44. doi: 10.2165/00148581-200507040-00003.
    1. Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol. 2000;55(9):659–67. doi: 10.1053/crad.2000.0490.
    1. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004;91(Suppl 2):S18–23. doi: 10.1038/sj.bjc.6602063.
    1. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301–26. doi: 10.1159/000079633.
    1. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91(Suppl 2):S3–10. doi: 10.1038/sj.bjc.6602061.
    1. Patel RR, Ryu JH, Vassallo R. Cigarette smoking and diffuse lung disease. Drugs. 2008;68(11):1511–27. doi: 10.2165/00003495-200868110-00004.
    1. Vlahovic G, Russell ML, Mercer RR, Crapo JD. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med. 1999;160(6):2086–92.
    1. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J. 2008;31(1):11–20. doi: 10.1183/09031936.00060107.
    1. Cottin V. Interstitial lung disease in connective tissue diseases. Rev Prat. 2007;57(20):2235–42.
    1. Guthrie KA, Tishkevich NR, Nelson JL. Non-inherited maternal human leukocyte antigen alleles in susceptibility to familial rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):107–9. doi: 10.1136/ard.2008.092312.
    1. Crow MK. Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesis. Curr Rheumatol Rep. 2008;10(3):165–7. doi: 10.1007/s11926-008-0028-3.
    1. Foeldvari I. Current developments in pediatric systemic sclerosis. Curr Rheumatol Rep. 2009;11(2):97–102. doi: 10.1007/s11926-009-0014-4.
    1. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009;11(2):111–9. doi: 10.1007/s11926-009-0016-2.
    1. du Bois RM. Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc. 2007;4(5):434–8. doi: 10.1513/pats.200608-152MS.
    1. Rigante D. Clinical overview of vasculitic syndromes in the pediatric age. Eur Rev Med Pharmacol Sci. 2006;10(6):337–45.
    1. Cabral DA, Uribe AG, Benseler S, O'Neil KM, Hashkes PJ, Higgins G. et al.Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413–24. doi: 10.1002/art.24876.
    1. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA. Incidence of Wegener's granulomatosis in children. J Rheumatol. 2010;37(2):440–2. doi: 10.3899/jrheum.090688.
    1. Pagnoux C. Wegener's granulomatosis and microscopic polyangiitis. Rev Prat. 2008;58(5):522–32.
    1. Lhote F. Churg-Strauss syndrome. Presse Med. 2007;36(5 Pt 2):875–89. doi: 10.1016/j.lpm.2007.02.018.
    1. Kawakami T, Soma Y. Churg-Strauss Syndrome in childhood: a clinical review. J Rheumatol. 2009;36(11):2622–3. doi: 10.3899/jrheum.090324.
    1. Ooi JD, Holdsworth SR, Kitching AR. Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. J Autoimmun. 2008;31(3):295–300. doi: 10.1016/j.jaut.2008.04.005.
    1. Kitagawa W, Imai H, Komatsuda A, Maki N, Wakui H, Hiki Y. et al.The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant. 2008;23(10):3126–9. doi: 10.1093/ndt/gfn179.
    1. Trisolini R, Cancellieri A, Paioli D, Burzi M, Orlandi P, Patelli M. Sarcoidosis in the setting of idiopathic chronic bronchiolitis with airway colonization from P. aeruginosa: treatment with low-dose macrolides. Intern Med. 2008;47(6):537–42. doi: 10.2169/internalmedicine.47.0675.
    1. Moller DR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc. 2007;4(5):465–8. doi: 10.1513/pats.200608-155MS.
    1. Fauroux B, Clément A. Pediatric sarcoidosis. Pediatr Respir Rev. 2005;6:128–33. doi: 10.1016/j.prrv.2005.03.007.
    1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65. doi: 10.1056/NEJMra071714.
    1. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93:30–6. doi: 10.1111/j.1651-2227.2004.tb00670.x.
    1. Baculard A, Blanc N, Boulé M, Fauroux B, Chadelat K, Boccon-Gibod L. et al.Pulmonary sarcoidosis in children: a follow-up study. Eur Respir J. 2001;17:628–35. doi: 10.1183/09031936.01.17406280.
    1. Clement A, Epaud R, Fauroux B. Sarcoidosis in children. Ltd ERJ, Eur Respir Monograph. 2005. pp. 251–8.
    1. Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J. 2008;31(3):592–8. doi: 10.1183/09031936.00011507.
    1. Chadelat K, Baculard A, Grimfeld A, Tournier G, Boulé M, Boccon-Gibod L. et al.Pulmonary sarcoidosis in children: serial evaluation in bronchoalveolar lavage cells during corticosteroid treatment. Pediatr Pulmonol. 1993;16:41–7. doi: 10.1002/ppul.1950160109.
    1. Stasia MJ, Cathebras P, Lutz MF, Durieu I. Chronic-granulomatous disease. Rev Med Interne. 2009;30(3):221–32. doi: 10.1016/j.revmed.2008.05.023.
    1. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L. et al.Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234. doi: 10.1371/journal.pone.0005234.
    1. Miller A, Brown LK, Pastores GM, Desnick RJ. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet. 2003;63(5):368–76. doi: 10.1034/j.1399-0004.2003.00060.x.
    1. Guillemot N, Troadec C, de Villemeur TB, Clement A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42(12):1207–14. doi: 10.1002/ppul.20725.
    1. Morgenthau AS, Padilla ML. Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med. 2009;76(1):2–23. doi: 10.1002/msj.20087.
    1. Demedts M, Lissens W, Wuyts W, Matthijs G, Thomeer M, Bouillon R. A new missense mutation in the CASR gene in familial interstitial lung disease with hypocalciuric hypercalcemia and defective granulocyte function. Am J Respir Crit Care Med. 2008;177(5):558–9.
    1. Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008;20(1):23–9. doi: 10.1097/MOP.0b013e3282f45ba4.
    1. Soler P, Tazi A, Hance AJ. Pulmonary Langerhans cell granulomatosis. Curr Opin Pulm Med. 1995;1(5):406–16.
    1. Carvalho RS, Wilson L, Cuffari C. Pulmonary manifestations in a pediatric patient with ulcerative colitis: a case report. J Med Case Reports. 2008;2:59. doi: 10.1186/1752-1947-2-59.
    1. Shen M, Zhang F, Zhang X. Primary Biliary Cirrhosis Complicated With Interstitial Lung Disease: A Prospective Study in 178 Patients. J Clin Gastroenterol. 2009.
    1. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y. et al.Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol. 2008;14(38):5880–6. doi: 10.3748/wjg.14.5880.
    1. Zamora AC, Collard HR, Wolters PJ, Webb WR, King TE. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007;29(1):210–4. doi: 10.1183/09031936.06.00044006.
    1. Vannella KM, Moore BB. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair. 2008;1(1):2. doi: 10.1186/1755-1536-1-2.
    1. Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol. 2008;43(1):1–10. doi: 10.1002/ppul.20676.
    1. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25. doi: 10.1186/1750-1172-3-25.
    1. Herold S, von Wulffen W, Steinmueller M, Pleschka S, Kuziel WA, Mack M. et al.Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol. 2006;177(3):1817–24.
    1. Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G. et al.HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol. 2008;26(1 Suppl 48):S39–47.
    1. Warshamana GS, Pociask DA, Fisher KJ, Liu JY, Sime PJ, Brody AR. Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice. Int J Exp Pathol. 2002;83(4):183–201. doi: 10.1046/j.1365-2613.2002.00229.x.
    1. Mora AL, Torres-Gonzalez E, Rojas M, Xu J, Ritzenthaler J, Speck SH. et al.Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. Am J Respir Crit Care Med. 2007;175(11):1139–50. doi: 10.1164/rccm.200610-1426OC.
    1. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS. et al.Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003;41(6):2633–40. doi: 10.1128/JCM.41.6.2633-2640.2003.
    1. Sikkel MB, Quint JK, Mallia P, Wedzicha JA, Johnston SL. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J. 2008;27(10 Suppl):S63–70.
    1. Welliver TP, Reed JL, Welliver RC. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J. 2008;27(10 Suppl):S92–6.
    1. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108–19. doi: 10.1038/modpathol.3800725.
    1. Webley WC, Tilahun Y, Lay K, Patel K, Stuart ES, Andrzejewski C. et al.Occurrence of Chlamydia trachomatis and Chlamydia pneumoniae in paediatric respiratory infections. Eur Respir J. 2009;33(2):360–7. doi: 10.1183/09031936.00019508.
    1. Marc E, Chaussain M, Moulin F, Iniguez JL, Kalifa G, Raymond J. et al.Reduced lung diffusion capacity after Mycoplasma pneumoniae pneumonia. Pediatr Infect Dis J. 2000;19(8):706–10.
    1. Ballard PL, Nogee LM, Beers MF, Ballard RA, Planer BC, Polk L. et al.Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics. 1995;96(6):1046–52.
    1. Dunbar AE, Wert SE, Ikegami M, Whitsett JA, Hamvas A, White FV. et al.Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation. Pediatr Res. 2000;48(3):275–82. doi: 10.1203/00006450-200009000-00003.
    1. Garmany TH, Moxley MA, White FV, Dean M, Hull WM, Whitsett JA. et al.Surfactant composition and function in patients with ABCA3 mutations. Pediatr Res. 2006;59(6):801–5. doi: 10.1203/01.pdr.0000219311.14291.df.
    1. Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H. et al.ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem. 2007;282(13):9628–34. doi: 10.1074/jbc.M611767200.
    1. Cheong N, Zhang H, Madesh M, Zhao M, Yu K, Dodia C. et al.ABCA3 is critical for lamellar body biogenesis in vivo. J Biol Chem. 2007;282(33):23811–7. doi: 10.1074/jbc.M703927200.
    1. Fitzgerald ML, Xavier R, Haley KJ, Welti R, Goss JL, Brown CE. et al.ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res. 2007;48(3):621–32. doi: 10.1194/jlr.M600449-JLR200.
    1. Nogee LM. Genetics of pediatric interstitial lung disease. Curr Opin Pediatr. 2006;18(3):287–92. doi: 10.1097/01.mop.0000193310.22462.1f.
    1. Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008;134(1):192–5. doi: 10.1378/chest.07-2652.
    1. Park SK, Amos L, Rao A, Quasney MW, Matsumura Y, Inagaki N. et al.Identification and characterization of a novel ABCA3 mutation. Physiol Genomics. 2010;40(2):94–9. doi: 10.1152/physiolgenomics.00123.2009.
    1. Devriendt K, Vanhole C, Matthijs G, de Zegher F. Deletion of thyroid transcription factor-1 gene in an infant with neonatal thyroid dysfunction and respiratory failure. N Engl J Med. 1998;338(18):1317–8. doi: 10.1056/NEJM199804303381817.
    1. Krude H, Schutz B, Biebermann H, von Moers A, Schnabel D, Neitzel H. et al.Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest. 2002;109(4):475–80.
    1. Pohlenz J, Dumitrescu A, Zundel D, Martine U, Schonberger W, Koo E. et al.Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. J Clin Invest. 2002;109(4):469–73.
    1. Doyle DA, Gonzalez I, Thomas B, Scavina M. Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J Pediatr. 2004;145(2):190–3. doi: 10.1016/j.jpeds.2004.04.011.
    1. Willemsen MA, Breedveld GJ, Wouda S, Otten BJ, Yntema JL, Lammens M. et al.Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr. 2005;164(1):28–30. doi: 10.1007/s00431-004-1559-x.
    1. Devos D, Vuillaume I, de Becdelievre A, de Martinville B, Dhaenens CM, Cuvellier JC. et al.New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. Mov Disord. 2006;21(12):2237–40. doi: 10.1002/mds.21135.
    1. Carre A, Szinnai G, Castanet M, Sura-Trueba S, Tron E, Broutin-L'Hermite I. et al.Five new TTF1/NKX2.1 mutations in brain-lung-thyroid syndrome: rescue by PAX8 synergism in one case. Hum Mol Genet. 2009;18(12):2266–76. doi: 10.1093/hmg/ddp162.
    1. Maquet E, Costagliola S, Parma J, Christophe-Hobertus C, Oligny LL, Fournet JC. et al.Lethal respiratory failure and mild primary hypothyroidism in a term girl with a de novo heterozygous mutation in the TITF1/NKX2.1 gene. J Clin Endocrinol Metab. 2009;94(1):197–203. doi: 10.1210/jc.2008-1402.
    1. Guillot L, Carre A, Szinnai G, Castanet M, Tron E, Jaubert F. et al.NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in "Brain-Lung-Thyroid Syndrome". Hum Mutat. 2010;31(2):E1146–62. doi: 10.1002/humu.21183.
    1. Latzin P, Tredano M, Wust Y, de Blic J, Nicolai T, Bewig B. et al.Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax. 2005;60(1):39–44. doi: 10.1136/thx.2004.021329.
    1. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE. et al.Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009;113(11):2547–56.
    1. Wang X, Liu F, Bewig B. Analysis of the GM-CSF and GM-CSF/IL-3/IL-5 receptor common beta chain in a patient with pulmonary alveolar proteinosis. Chin Med J (Engl) 2002;115(1):76–80. doi: 10.3901/JME.2002.supp.076.
    1. Nathan N, Guillemot N, Aubertin G, Blanchon S, Chadelat K, Epaud R. et al.Chronic eosinophilic pneumonia in a 13-year-old child. Eur J Pediatr. 2008;167(10):1203–7. doi: 10.1007/s00431-007-0648-z.
    1. Allen J. Acute eosinophilic pneumonia. Semin Respir Crit Care Med. 2006;27(2):142–7. doi: 10.1055/s-2006-939517.
    1. Jeong YJ, Kim KI, Seo IJ, Lee CH, Lee KN, Kim KN. et al.Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007;27(3):617–37. doi: 10.1148/rg.273065051. discussion 37-9.
    1. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007;2:37. doi: 10.1186/1750-1172-2-37.
    1. Merchak A, Lueder GT, White FV, Cole FS. Alveolar capillary dysplasia with misalignment of pulmonary veins and anterior segment dysgenesis of the eye: a report of a new association and review of the literature. J Perinatol. 2001;21(5):327–30. doi: 10.1038/sj.jp.7200494.
    1. Michalsky MP, Arca MJ, Groenman F, Hammond S, Tibboel D, Caniano DA. Alveolar capillary dysplasia: a logical approach to a fatal disease. J Pediatr Surg. 2005;40(7):1100–5. doi: 10.1016/j.jpedsurg.2005.03.067.
    1. Somaschini M, Bellan C, Chinaglia D, Riva S, Colombo A. Congenital misalignment of pulmonary vessels and alveolar capillary dysplasia: how to manage a neonatal irreversible lung disease? J Perinatol. 2000;20(3):189–92. doi: 10.1038/sj.jp.7200335.
    1. Almagro P, Julia J, Sanjaume M, Gonzalez G, Casalots J, Heredia JL. et al.Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 2002;81(6):417–24. doi: 10.1097/00005792-200211000-00002.
    1. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol. 2006;30(7):850–7. doi: 10.1097/01.pas.0000209834.69972.e5.
    1. El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G. et al.Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci USA. 2009;106(10):3958–63. doi: 10.1073/pnas.0813368106.
    1. Epaud R, Dubern B, Larroquet M, Tamalet A, Guillemot N, Maurage C. et al.Therapeutic strategies for idiopathic chylothorax. J Pediatr Surg. 2008;43(3):461–5. doi: 10.1016/j.jpedsurg.2007.10.024.
    1. Barker P. Pulmonary Lymphangiectasia British Paediatric Orphan Lung Diseases (BPOLD)
    1. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ. et al.Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest. 2005;115(2):247–57.
    1. Susarla SC, Fan LL. Diffuse alveolar hemorrhage syndromes in children. Curr Opin Pediatr. 2007;19(3):314–20. doi: 10.1097/MOP.0b013e3280dd8c4a.
    1. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med. 2008;75(4) doi: 10.3949/ccjm.75.4.258. 258, 60, 64-5 passim.
    1. Nuesslein TG, Teig N, Rieger CH. Pulmonary haemosiderosis in infants and children. Paediatr Respir Rev. 2006;7(1):45–8. doi: 10.1016/j.prrv.2005.11.003.
    1. Moissidis I, Chaidaroon D, Vichyanond P, Bahna SL. Milk-induced pulmonary disease in infants (Heiner syndrome) Pediatr Allergy Immunol. 2005;16(6):545–52. doi: 10.1111/j.1399-3038.2005.00291.x.
    1. Laurent GJ, McAnulty RJ, Hill M, Chambers R. Escape from the matrix: multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc Am Thorac Soc. 2008;5(3):311–5. doi: 10.1513/pats.200710-159DR.
    1. Wallach-Dayan SB, Golan-Gerstl R, Breuer R. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc Natl Acad Sci USA. 2007;104(51):20460–5. doi: 10.1073/pnas.0705582104.
    1. Meyerholz DK, DeGraaff JA, Gallup JM, Olivier AK, Ackermann MR. Depletion of alveolar glycogen corresponds with immunohistochemical development of CD208 antigen expression in perinatal lamb lung. J Histochem Cytochem. 2006;54(11):1247–53. doi: 10.1369/jhc.6A7002.2006.
    1. Ridsdale R, Post M. Surfactant lipid synthesis and lamellar body formation in glycogen-laden type II cells. Am J Physiol Lung Cell Mol Physiol. 2004;287(4):L743–51. doi: 10.1152/ajplung.00146.2004.
    1. Canakis AM, Cutz E, Manson D, O'Brodovich H. Pulmonary interstitial glycogenosis: a new variant of neonatal interstitial lung disease. Am J Respir Crit Care Med. 2002;165(11):1557–65. doi: 10.1164/rccm.2105139.
    1. Langston C, Dishop M. Diffuse Lung Disease in Infancy a Proposed Classification Applied to 259 Diagnostic Biopsies. Pediatr Dev Pathol. 2009;26(6):421–437. doi: 10.2350/08-11-0559.1.
    1. Onland W, Molenaar JJ, Leguit RJ, van Nierop JC, Noorduyn LA, van Rijn RR. et al.Pulmonary interstitial glycogenosis in identical twins. Pediatr Pulmonol. 2005;40(4):362–6. doi: 10.1002/ppul.20255.
    1. Smets K, Dhaene K, Schelstraete P, Meersschaut V, Vanhaesebrouck P. Neonatal pulmonary interstitial glycogen accumulation disorder. Eur J Pediatr. 2004;163(7):408–9. doi: 10.1007/s00431-004-1450-9.
    1. Weichselbaum M, Sparrow MP, Hamilton EJ, Thompson PJ, Knight DA. A confocal microscopic study of solitary pulmonary neuroendocrine cells in human airway epithelium. Respir Res. 2005;6:115. doi: 10.1186/1465-9921-6-115.
    1. Cutz E, Yeger H, Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. Pediatr Dev Pathol. 2007;10(6):419–35. doi: 10.2350/07-04-0267.1.
    1. Sunday ME, Wolfe HJ, Roos BA, Chin WW, Spindel ER. Gastrin-releasing peptide gene expression in developing, hyperplastic, and neoplastic human thyroid C-cells. Endocrinology. 1988;122(4):1551–8. doi: 10.1210/endo-122-4-1551.
    1. Deterding RR, Pye C, Fan LL, Langston C. Persistent tachypnea of infancy is associated with neuroendocrine cell hyperplasia. Pediatr Pulmonol. 2005;40(2):157–65. doi: 10.1002/ppul.20243.
    1. Brody AS, Crotty EJ. Neuroendocrine cell hyperplasia of infancy (NEHI) Pediatr Radiol. 2006;36(12):1328. doi: 10.1007/s00247-006-0302-3.
    1. Desmarquest P, Tamalet A, Fauroux B, Boulé M, Boccon-Gobod L, Tournier G. et al.Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses. Pediatr Pulmonol. 1998;26:332–8. doi: 10.1002/(SICI)1099-0496(199811)26:5<332::AID-PPUL5>;2-Q.
    1. Avital A, Godfrey S, Maayan C, Diamant Y, Springer C. Chloroquine treatment of interstitial lung disease in children. Pediatr Pulmonol. 1994;18(6):356–60. doi: 10.1002/ppul.1950180603.
    1. Balasubramanyan N, Murphy A, O'Sullivan J, O'Connell EJ. Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. Pediatr Pulmonol. 1997;23(1):55–61. doi: 10.1002/(SICI)1099-0496(199701)23:1<55::AID-PPUL7>;2-O.
    1. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331–50.
    1. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009;22(6):467–72. doi: 10.1016/j.pupt.2009.03.002.
    1. Knyazhitskiy A, Masson RG, Corkey R, Joiner J. Beneficial response to macrolide antibiotic in a patient with desquamative interstitial pneumonia refractory to corticosteroid therapy. Chest. 2008;134(1):185–7. doi: 10.1378/chest.07-2786.
    1. de Blic J. Pulmonary alveolar proteinosis in children. Paediatr Respir Rev. 2004;5(4):316–22. doi: 10.1016/j.prrv.2004.07.001.
    1. Ho V, Krol A, Bhargava R, Osiovich H. Diffuse neonatal haemangiomatosis. J Paediatr Child Health. 2000;36(3):286–9. doi: 10.1046/j.1440-1754.2000.00491.x.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera